Maxim Group downgraded Immune Pharmaceuticals (OTCQB:IMNP) to “hold” from “buy” and removed its prior price target of $2 as the company continues to resolve its financing overhang. The stock closed at 13 cents on Aug. 3...

Ladenburg Thalmann initiated coverage of Allena Pharmaceuticals (NASDAQ:ALNA) with a “buy” rating and $23 price target. The stock closed at $10.49 on August 1. Allena’s developmental program is focused on the reduction...

H.C. Wainwright slashed its price target for SELLAS Life Sciences (NASDAQ:SLS) to $4 from $11 after the company completed a $21.6-million offering of common shares, pre-funded warrants and warrants in July. The stock...

Echelon Wealth Partners downgraded Arbutus Biopharma (NASDAQ:ABUS) to “hold” from “speculative buy” with a price target of $12.25 based on valuation. The stock was quoted at $11.40 at midday on July 27. Analyst Doug Loe...

Roth Capital Partners downgraded Tonix Pharmaceuticals (NASDAQ:TNXP) to “neutral” from “buy” with a price target of $1 after the company posted disappointing results from its interim Phase 3 analysis of Tonmya for the...

Leerink raised its price target for resTORbio (NASDAQ:TORC) to $45 from $35 after the company announced positive top-line results from its Phase 2b clinical trial of RTB101. The stock finished at $13.47 on July 25. The...

Alliance Global Partners launched coverage of Profound Medical (OTCQX:PRFMF; TSX:PRN) with a “buy” rating and price target of $1.60. The stock closed at 70 cents on July 24. Analyst Ben Haynor writes that the...

Canaccord Genuity initiated coverage of Neuronetics (NASDAQ:STIM) with a “buy” rating and $33 price target. The stock closed at $26.02 on July 23. “Possessing a clinically validated, proprietary, non-invasive technology...

Roth Capital Partners launched coverage of Menlo Therapeutics (NASDAQ:MNLO) with a “buy” rating and $29 price target. The stock finished at $7.50 on July 23. Yasmeen Rahimi writes that the company has a Phase 3 asset...

Canaccord Genuity initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with a “buy” rating and price target of $2. The stock closed at 94 cents on July 23. “Profound Medical has the makings of an exciting med...

Analysts at Piper Jaffray, William Blair and BTIG launched coverage of Neuronetics (NASDAQ:STIM) with “overweight, outperform and buy” ratings, respectively. The stock closed at $26.53 on July 20. “Although the company...

Leerink initiated coverage of Translate Bio (NASDAQ:TBIO) with an “outperform” rating and $24 price target. The stock closed at $15.94 on July 20. Translate Bio is developing MRT5005, a messenger RNA (mRNA)-based...

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

H.C. Wainwright initiated coverage of Innovate Biopharmaceuticals (NASDAQ:INNT) with a “buy” rating and $35 price target. The stock finished at $8.08 on July 17. Innovate is focused on two clinical-stage assets aimed at...

William Blair launched coverage of Autolus Therapeutics (NASDAQ:AUTL) with an “outperform” rating and risk-adjusted valuation of roughly $38. The stock closed at $20.86 on July 17. “Based on our view, the company’s next...

BTIG initiated coverage of electroCore (NASDAQ:ECOR) with a “buy” rating and $20 price target. The stock closed at $14.64 on July 16. electroCore has developed an FDA-cleared non-invasive vagus nerve stimulation device...

H.C. Wainwright initiated coverage of Sol-Gel Technologies (NASDAQ:SLGL) with a “buy” rating and price target of $21. The stock closed at $6.97 on July 13. The company’s lead drug candidates, TWIN and VERED, are...

William Blair initiated coverage of Kezar Life Sciences (NASDAQ:KZR) with an “outperform” rating and fair value estimate of $25. The stock closed at $16.50 on July 13. Analyst Matthew Phipps writes the company’s novel...

H.C. Wainwright launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with a “buy” rating and $45 price target. The stock closed at $27.06 on July 13. Adamas’ lead product, GOCOVRI, was approved in August 2017 in...

Ladenburg Thalmann upgraded Vericel (NASDAQ:VCEL) to “buy” from “neutral” and introduced a price target of $13. The stock closed at $9.10 on July 13. “We believe Vericel shares are oversold and would be buyers of the...

Stifel launched coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and price target of $35. The stock closed at $12.77 on July 12. “We think Galmed’s lead, wholly-owned asset, Aramchol, has...

H.C. Wainwright initiated coverage of Syndax Pharmaceuticals (NASDAQ:SNDX) with a “buy” rating and a $30 price target. The stock closed at $7.10 on July 11. Analyst Edward White writes that Syndax’s lead candidate...